<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03955393</url>
  </required_header>
  <id_info>
    <org_study_id>FAZA RCC LNI</org_study_id>
    <nct_id>NCT03955393</nct_id>
  </id_info>
  <brief_title>FAZA PET IMAGING IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS</brief_title>
  <acronym>FAZA</acronym>
  <official_title>THE ROLE OF 18F-FAZA PET IMAGING TECHNIQUE IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In renal cell carcinoma (RCC) patients, lymph node metastases detection and treatment are the
      most critical issues in daily clinical decision-making. Indeed, conversely to other
      oncological settings, a) nodal status imaging, b) sentinel node technique and c) standard
      lymphadenectomy have been demonstrated inadequate in the staging and management of RCC
      patients. A novel, accurate, standardized imaging technique is urgently needed in RCC setting
      to detect macro and micro nodal invasion, to identify those patients who are at higher risk
      of having nodal metastases, to accurately plan the best management. Recent studies suggested
      combining 18F-FAZA PET with CT scanning in the detection of cancer-induced hypoxia.The
      investigators propose to test 18F-FAZA PET-CT in detecting nodal metastases to improve the
      management of RCC patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">April 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Test the performance of 18F-FAZA</measure>
    <time_frame>120 minutes</time_frame>
    <description>To test the performance of 18F-FAZA PET technique in detecting nodal metastases in RCC patients</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Renal Cell Carcinoma (RCC)</condition>
  <arm_group>
    <arm_group_label>LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS</arm_group_label>
    <description>Twenty patients candidates to radical nephrectomy and extended lymphadenectomy for clinical T4 cancers (clinical Nany) or renal masses with evidence of lymphadenopathies at preoperative CT scan (clinical Tany N1) or larger tumor (clinical Tany Nany and max diameter&gt;10 cm). RCC candidates to surgery will receive a single intravenous infusion of 18F-FAZA. Surgery will be scheduled within 1 week after infusion. PET and CT scanning of the abdomen will be planned before surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>18F-FAZA PET IMAGING TECHNIQUE IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS</intervention_name>
    <description>18F-FAZA is a highly selective PET radiotracer of hypoxia, which has been recently developed and tested in several studies (10-14). 18F-FAZA has been demonstrated to be a marker of hypoxia and pathological metabolic patterns which are common to all renal cancers.</description>
    <arm_group_label>LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS</arm_group_label>
    <other_name>18F-FAZA</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients candidates to radical nephrectomy and extended lymphadenectomy for clinical T4
        cancers (clinical Nany) or renal masses with evidence of lymphadenopathies at preoperative
        CT scan (clinical Tany N1) or larger tumor (clinical Tany Nany and max diameter&gt;10 cm).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age of at least 18 years with diagnosis of RCC;

          -  patients candidates to radical nephrectomy and extended lymphadenectomy

          -  clinical T4 cancers or renal masses with evidence of lymphadenopathies at preoperative
             CT scan or larger tumor (max diameter&gt;10 cm)

          -  performance status 0-1;

          -  expected survival time of at least 3 months;

          -  recovery from toxic effects of any previous treatment;

          -  serum biochemical and haematological measurements within healthy parameters.

          -  Female patients of childbearing age were requested to have a negative pregnancy test

          -  ability to understand and understand informed consent

          -  acceptance and signature of informed consent

        Exclusion Criteria:

          -  other medical conditions that might limit the amount of antibody to be administered;

          -  New York Heart Association Class III/IV cardiac disease;

          -  pregnancy and breastfeeding

          -  eGFR&lt;30;

          -  women of child-bearing age who do not agree to use contraceptives to avoid pregnancy;

          -  history of autoimmune hepatitis;

          -  allergy to iodine;

          -  unavailability or immunological and clinical follow-up assessments;

          -  participation in another clinical trial involving an investigational agent within 4
             weeks of study enrolment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IRCCS San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC; European Association of Urology Guideline Group. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010 Sep;58(3):398-406. doi: 10.1016/j.eururo.2010.06.032. Epub 2010 Jul 12.</citation>
    <PMID>20633979</PMID>
  </reference>
  <reference>
    <citation>Capitanio U, Becker F, Blute ML, Mulders P, Patard JJ, Russo P, Studer UE, Van Poppel H. Lymph node dissection in renal cell carcinoma. Eur Urol. 2011 Dec;60(6):1212-20. doi: 10.1016/j.eururo.2011.09.003. Epub 2011 Sep 13. Review.</citation>
    <PMID>21940096</PMID>
  </reference>
  <reference>
    <citation>Studer UE, Scherz S, Scheidegger J, Kraft R, Sonntag R, Ackermann D, Zingg EJ. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol. 1990 Aug;144(2 Pt 1):243-5.</citation>
    <PMID>2374186</PMID>
  </reference>
  <reference>
    <citation>Lughezzani G, Capitanio U, Jeldres C, Isbarn H, Shariat SF, Arjane P, Widmer H, Perrotte P, Montorsi F, Karakiewicz PI. Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective. Cancer. 2009 Dec 15;115(24):5680-7. doi: 10.1002/cncr.24682.</citation>
    <PMID>19824083</PMID>
  </reference>
  <reference>
    <citation>Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol. 2001 Jul;166(1):68-72.</citation>
    <PMID>11435825</PMID>
  </reference>
  <reference>
    <citation>Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2009 Apr;55(4):815-25. doi: 10.1016/j.eururo.2009.01.002. Epub 2009 Jan 13. Review.</citation>
    <PMID>19157687</PMID>
  </reference>
  <reference>
    <citation>Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F; European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011 Jan;59(1):61-71. doi: 10.1016/j.eururo.2010.10.039. Epub 2010 Oct 28.</citation>
    <PMID>21056534</PMID>
  </reference>
  <reference>
    <citation>Blom JH, van Poppel H, Maréchal JM, Jacqmin D, Schröder FH, de Prijck L, Sylvester R; EORTC Genitourinary Tract Cancer Group. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol. 2009 Jan;55(1):28-34. doi: 10.1016/j.eururo.2008.09.052. Epub 2008 Oct 1.</citation>
    <PMID>18848382</PMID>
  </reference>
  <reference>
    <citation>Beyer T, Czernin J, Freudenberg LS. Variations in clinical PET/CT operations: results of an international survey of active PET/CT users. J Nucl Med. 2011 Feb;52(2):303-10. doi: 10.2967/jnumed.110.079624. Epub 2011 Jan 13.</citation>
    <PMID>21233186</PMID>
  </reference>
  <reference>
    <citation>Studer UE, Birkhäuser FD. Lymphadenectomy combined with radical nephrectomy: to do or not to do? Eur Urol. 2009 Jan;55(1):35-7. doi: 10.1016/j.eururo.2008.09.056. Epub 2008 Oct 7.</citation>
    <PMID>18848383</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <last_update_submitted>May 18, 2019</last_update_submitted>
  <last_update_submitted_qc>May 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Umberto Capitanio</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>LYMPH NODE METASTASES</keyword>
  <keyword>18F-FAZA PET IMAGING TECHNIQUE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoroazomycin arabinoside</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

